Hiko Adem, Seifu Belayneh
College of Veterinary Medicine, Haramaya University, Po. Box. 138, Dire Dawa, Ethiopia.
Parasite Epidemiol Control. 2018 Nov 17;4:e00078. doi: 10.1016/j.parepi.2018.e00078. eCollection 2019 Feb.
A metacestode stage (bovine cysticercosis) and adult stage , accounted for zoonotic and economic losses from organ contamination and treatment cost. The objective of this paper is to assess the spatiotemporal distribution and economic loss from bovine cysticercosis and human taeniasis with treatment approach in different parts of Ethiopia. All available published research articles from Ethiopia on the disease were collected. The data were assessed using the current regional administrative, the locality and chronology of the reports for prevalence and economic loss with treatment trend. Prevalence ranging from 1.9% at Addis Ababa City to as high as of 26.3% Hawasa-SNNPR using postmortem examination. However, one study confirmed 92.7% of 41 isolates as bovine cysticercosis using polymerase chain reaction (PCR) method. Teaniasis was ranged from 7.8% in Modjo-Oromia to as high as 89.4% in Addis Ababa City. Except for 17.9% at Addis Ababa City, 29.0% at Mekele-Tigray and 19.0% at Halaba Kulito -SNNPR teaniasis in Ethiopia were greater than 30% over 2001-2018 years. Questionnaire survey and retrospective data were the major tools used for teaniasis reporting either pharmaceutical and/or traditional (herbs) medicines were used for teaniasis treatments. Niclosamide, mebendazole and praziquantel were pharmaceutical teaniacidal drugs used in Ethiopia until the years of 2009, uses of albendazole begins from 2011 to date (2018 year). "Kosso/Heto" flowers is still widely used in Ethiopia in that it contains Kosso-toxin, closely related to folic acid, are responsible for some cases of hepatic carcinoma and blindness. Only few data (reports) were available on spatiotemporal economic loss associated with bovine cysticercosis and in Ethiopia showing an overall 4,052,278.16 ETB (212,202.76 USD) from five reports. Highest economic loss (88,500.00 USD) was registered at Yirgalem-SNNPR [2005-2009]. Study at Kombolcha-Amhara region during 2016 accounted 1,841,311.00ETB (73,652.44 USD) from and teaniasis treatment cost. Total cost for the used pharmaceutical drugs accounted 921,112.00ETB over 2005-2016. The maximum drug expenditure was reported during the year 2013. Thus, bovine cysticercosis and in Ethiopia indicating the health and economic challenges. It needs to cycle interruption via stopping human open defecation with assessing the dynamics of the disease in the country.
牛带绦虫蚴阶段(牛囊尾蚴病)和成虫阶段会造成人畜共患病以及因器官感染和治疗费用导致的经济损失。本文旨在评估埃塞俄比亚不同地区牛囊尾蚴病和人体绦虫病的时空分布及经济损失,并探讨治疗方法。收集了埃塞俄比亚所有已发表的关于该疾病的研究文章。利用当前的地区行政区划、报告的地点和时间顺序,对患病率和经济损失以及治疗趋势的数据进行评估。通过尸检发现,患病率从亚的斯亚贝巴市的1.9%到哈瓦萨-南苏丹民族人民地区高达26.3%不等。然而,一项研究使用聚合酶链反应(PCR)方法确认41个分离株中有92.7%为牛囊尾蚴病。人体绦虫病的患病率从莫乔-奥罗米亚的7.8%到亚的斯亚贝巴市高达89.4%。在2001年至2018年期间,除了亚的斯亚贝巴市的17.9%、梅克内-提格雷的29.0%和哈拉巴库里托-南苏丹民族人民地区的19.0%外,埃塞俄比亚人体绦虫病的患病率超过30%。问卷调查和回顾性数据是报告人体绦虫病的主要工具,治疗人体绦虫病使用的药物包括西药和/或传统(草药)药物。直到2009年,氯硝柳胺、甲苯咪唑和吡喹酮一直是埃塞俄比亚使用的治疗绦虫病的西药,阿苯达唑从2011年开始使用至今(2018年)。“科索/赫托”花在埃塞俄比亚仍被广泛使用,因为它含有与叶酸密切相关的科索毒素,会导致一些肝癌和失明病例。关于埃塞俄比亚与牛囊尾蚴病相关的时空经济损失的数据(报告)很少,五份报告显示总体经济损失为4,052,278.16埃塞俄比亚比尔(21,2202.76美元)。最高经济损失(88,500.00美元)记录在伊尔加莱姆-南苏丹民族人民地区[2005 - 2009年]。2016年在科姆博尔查-阿姆哈拉地区的研究表明,牛囊尾蚴病和人体绦虫病的治疗费用为1,841,311.00埃塞俄比亚比尔(73,652.44美元)。2005年至2016年期间,使用的西药总费用为921,112.00埃塞俄比亚比尔。最大的药物支出报告发生在2013年。因此,埃塞俄比亚的牛囊尾蚴病和人体绦虫病表明了健康和经济方面的挑战。需要通过停止人类露天排便来阻断传播循环,并评估该国该疾病的动态。